Datasets:

moneuron
/

aur-umb-dataset

ID int64 6 67	author stringclasses 23 values	year int64 2.01k 2.02k	cancerType stringclasses 13 values	cellLine stringclasses 27 values	time int64 8 144	coumarin stringclasses 2 values	coumarinDose float64 0.1 335	viability float64 3.66 109	viabilitySD float64 0.5 24.6	viabilityN int64 2 6	control float64 77.3 111	controlSD float64 0.86 12.5	controlN int64 2 6
6	Movaffagh et al.	2,021	Gastric	MKN-45	24	Auraptene	16.7	93.61	6.39	3	85.81	2.13	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	24	Auraptene	33.4	85.81	2.13	3	85.81	2.13	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	24	Auraptene	66.8	78.95	8.04	3	85.81	2.13	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	24	Auraptene	133.6	52	11.35	3	85.81	2.13	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	48	Auraptene	16.7	92.67	4.49	3	96.69	3.31	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	48	Auraptene	33.4	79.9	5.2	3	96.69	3.31	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	48	Auraptene	66.8	53.19	4.49	3	96.69	3.31	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	48	Auraptene	133.6	37.58	5.91	3	96.69	3.31	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	72	Auraptene	16.7	97.87	1.42	3	92.9	2.84	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	72	Auraptene	33.4	91.48	6.62	3	92.9	2.84	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	72	Auraptene	66.8	60.04	14.19	3	92.9	2.84	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	72	Auraptene	133.6	44.2	5.44	3	92.9	2.84	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	96	Auraptene	16.7	84.86	5.21	3	90.7	2.12	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	96	Auraptene	33.4	69.97	4.26	3	90.7	2.12	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	96	Auraptene	66.8	65.01	6.43	3	90.7	2.12	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	96	Auraptene	133.6	43.26	3.54	3	90.7	2.12	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	120	Auraptene	16.7	74.94	11.34	3	92.9	7.1	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	120	Auraptene	33.4	72.1	10.16	3	92.9	7.1	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	120	Auraptene	66.8	69.97	6.43	3	92.9	7.1	3
6	Movaffagh et al.	2,021	Gastric	MKN-45	120	Auraptene	133.6	41.13	5.67	3	92.9	7.1	3
8	Jamialahmadi et al.	2,018	Ovarian	A2780	24	Auraptene	31.49	50	5.83	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Cervical	Hela	24	Auraptene	47.93	50	5.83	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Ovarian	A2780	24	Auraptene	3.13	88.38	6.36	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Ovarian	A2780	24	Auraptene	6.25	82.32	2.38	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Ovarian	A2780	24	Auraptene	12.5	71.21	5.57	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Ovarian	A2780	24	Auraptene	25	55.34	6.1	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Ovarian	A2780	24	Auraptene	50	41.59	3.44	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Ovarian	A2780	24	Auraptene	100	22.53	0.79	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Cervical	Hela	24	Auraptene	3.13	88.35	11.65	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Cervical	Hela	24	Auraptene	6.25	85.44	7.41	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Cervical	Hela	24	Auraptene	12.5	72.25	19.84	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Cervical	Hela	24	Auraptene	25	69.04	5.03	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Cervical	Hela	24	Auraptene	50	64.28	9.26	3	100	3.36	3
8	Jamialahmadi et al.	2,018	Cervical	Hela	24	Auraptene	100	18.78	3.45	3	100	3.36	3
42	Abolhassani et al.	2,023	Prostate	PC3	48	Auraptene	5	93.33	8.23	3	95.68	3.13	3
42	Abolhassani et al.	2,023	Prostate	PC3	48	Auraptene	10	94.5	4.7	3	95.68	3.13	3
42	Abolhassani et al.	2,023	Prostate	PC3	48	Auraptene	20	92.15	6.66	3	95.68	3.13	3
42	Abolhassani et al.	2,023	Prostate	PC3	48	Auraptene	40	85.88	4.7	3	95.68	3.13	3
42	Abolhassani et al.	2,023	Prostate	PC3	48	Auraptene	80	65.88	6.27	3	95.68	3.13	3
42	Abolhassani et al.	2,023	Prostate	PC3	72	Auraptene	5	93.72	3.92	3	88.23	8.62	3
42	Abolhassani et al.	2,023	Prostate	PC3	72	Auraptene	10	85.88	7.84	3	88.23	8.62	3
42	Abolhassani et al.	2,023	Prostate	PC3	72	Auraptene	20	83.13	7.05	3	88.23	8.62	3
42	Abolhassani et al.	2,023	Prostate	PC3	72	Auraptene	40	76.86	10.19	3	88.23	8.62	3
42	Abolhassani et al.	2,023	Prostate	PC3	72	Auraptene	80	64.31	8.23	3	88.23	8.62	3
42	Abolhassani et al.	2,023	Prostate	PC3	96	Auraptene	5	92.94	7.84	3	81.56	8.23	3
42	Abolhassani et al.	2,023	Prostate	PC3	96	Auraptene	10	85.49	10.19	3	81.56	8.23	3
42	Abolhassani et al.	2,023	Prostate	PC3	96	Auraptene	20	81.56	3.13	3	81.56	8.23	3
42	Abolhassani et al.	2,023	Prostate	PC3	96	Auraptene	40	78.43	6.27	3	81.56	8.23	3
42	Abolhassani et al.	2,023	Prostate	PC3	96	Auraptene	80	49.41	1.96	3	81.56	8.23	3
42	Abolhassani et al.	2,023	Prostate	PC3	120	Auraptene	5	86.66	3.92	3	80.78	6.66	3
42	Abolhassani et al.	2,023	Prostate	PC3	120	Auraptene	10	81.17	8.62	3	80.78	6.66	3
42	Abolhassani et al.	2,023	Prostate	PC3	120	Auraptene	20	77.64	3.13	3	80.78	6.66	3
42	Abolhassani et al.	2,023	Prostate	PC3	120	Auraptene	40	73.72	5.88	3	80.78	6.66	3
42	Abolhassani et al.	2,023	Prostate	PC3	120	Auraptene	80	42.35	4.31	3	80.78	6.66	3
42	Abolhassani et al.	2,023	Prostate	PC3	144	Auraptene	5	79.6	4.7	3	77.25	6.66	3
42	Abolhassani et al.	2,023	Prostate	PC3	144	Auraptene	10	76.47	8.23	3	77.25	6.66	3
42	Abolhassani et al.	2,023	Prostate	PC3	144	Auraptene	20	73.72	3.13	3	77.25	6.66	3
42	Abolhassani et al.	2,023	Prostate	PC3	144	Auraptene	40	70.58	5.09	3	77.25	6.66	3
42	Abolhassani et al.	2,023	Prostate	PC3	144	Auraptene	80	34.9	5.88	3	77.25	6.66	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	24	Auraptene	16.7	99.25	4.32	3	99.38	3.11	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	24	Auraptene	33.5	100.37	2.47	3	99.38	3.11	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	24	Auraptene	67	99.04	3.7	3	99.38	3.11	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	24	Auraptene	134	97.71	3.09	3	99.38	3.11	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	48	Auraptene	16.7	103.91	2.47	3	103.43	2.47	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	48	Auraptene	33.5	96.98	3.09	3	103.43	2.47	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	48	Auraptene	67	84.53	3.7	3	103.43	2.47	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	48	Auraptene	134	76.37	4.34	3	103.43	2.47	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	72	Auraptene	16.7	105.6	9.87	3	110.65	8	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	72	Auraptene	33.5	102.49	10.49	3	110.65	8	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	72	Auraptene	67	87.02	4.32	3	110.65	8	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	72	Auraptene	134	75.27	8.02	3	110.65	8	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	96	Auraptene	16.7	80.24	7.95	3	82.62	6.41	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	96	Auraptene	33.5	78.18	6.43	3	82.62	6.41	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	96	Auraptene	67	62.05	4.28	3	82.62	6.41	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	96	Auraptene	134	45.63	6.42	3	82.62	6.41	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	120	Auraptene	16.7	91.8	3.67	3	91.46	3.06	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	120	Auraptene	33.5	82.35	1.83	3	91.46	3.06	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	120	Auraptene	67	60.04	9.48	3	91.46	3.06	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	120	Auraptene	134	47.54	6.12	3	91.46	3.06	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	144	Auraptene	16.7	88.86	1.83	3	88.2	3.67	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	144	Auraptene	33.5	78.25	6.41	3	88.2	3.67	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	144	Auraptene	67	56.34	7.95	3	88.2	3.67	3
44	Bagheri et al.	2,022	Leukemia/Lymphoma	MT-2	144	Auraptene	134	40.24	1.83	3	88.2	3.67	3
46	Afshari et al.	2,019	Glioblastoma	U87	8	Auraptene	167.6	70.16	2.76	3	100	1.65	3
46	Afshari et al.	2,019	Glioblastoma	U87	8	Auraptene	335.2	51.93	3.31	3	100	1.65	3
46	Afshari et al.	2,019	Glioblastoma	U87	24	Auraptene	167.6	57.91	3.34	3	100	2.09	3
46	Afshari et al.	2,019	Glioblastoma	U87	24	Auraptene	335.2	42.5	2.91	3	100	2.09	3
47	Epifano et al.	2,013	Colon	HT-29	72	Auraptene	2.5	90.94	4.53	3	99.62	12.45	3
47	Epifano et al.	2,013	Colon	HT-29	72	Auraptene	5	86.41	4.53	3	99.62	12.45	3
47	Epifano et al.	2,013	Colon	HT-29	72	Auraptene	10	75.09	7.55	3	99.62	12.45	3
47	Epifano et al.	2,013	Colon	HT-29	72	Auraptene	20	55.09	16.6	3	99.62	12.45	3
47	Epifano et al.	2,013	Colon	HT-29	72	Auraptene	40	28.3	2.26	3	99.62	12.45	3
47	Epifano et al.	2,013	Colon	HT-116	72	Auraptene	2.5	86.41	9.43	3	100	9.05	3
47	Epifano et al.	2,013	Colon	HT-116	72	Auraptene	5	84.9	19.62	3	100	9.05	3
47	Epifano et al.	2,013	Colon	HT-116	72	Auraptene	10	70.18	19.63	3	100	9.05	3
47	Epifano et al.	2,013	Colon	HT-116	72	Auraptene	20	56.6	3.77	3	100	9.05	3
47	Epifano et al.	2,013	Colon	HT-116	72	Auraptene	40	45.66	17.35	3	100	9.05	3
48	Moon et al.	2,015	Gastric	AGS	48	Auraptene	12.5	92.84	13.58	3	100	2.91	3
48	Moon et al.	2,015	Gastric	AGS	48	Auraptene	25	80.73	9.91	3	100	2.91	3
48	Moon et al.	2,015	Gastric	AGS	48	Auraptene	50	48.44	6.23	3	100	2.91	3

End of preview. Expand in Data Studio

Introduced by Shakiba et al. in Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: a meta-analysis

This dataset contains quantitative data on the anticancer effects of the natural coumarins Auraptene (AUR) and Umbelliprenin (UMB) across 27 studies. The data were collected from published literature reporting the impacts of AUR and UMB treatment on the viability of diverse human cancer cell lines.

The data are from published literature, as cited in this paper. The codes utilized in the paper are available at: https://github.com/moneuron/srep-meta-codes

author: First author's last name from publication
year: Publication year
cancerType: Cancer type examined
cellLine: Specific cell line utilized
time: Treatment duration (in hours)
coumarin: Coumarin used (AUR or UMB)
coumarinDose: Dosage of coumarin (in μM)
viability: Mean viability (%) in treatment group
viabilitySD: Standard deviation of treatment group viability
viabilityN: Number of repeats in treatment group
control: Mean viability (%) in control group
controlSD: Standard deviation of control group viability
controlN: Number of repeats in control group

Downloads last month: 37